#### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	No	n/a
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
<b>Cell lines:</b> Provide species information, strain.		
Provide accession number in repository <b>OR</b>	No	n/a
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of	No	n/a
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	No	n/a
genetic modification status. Provide accession		, -
number in repository <b>OR</b> supplier name, catalog		
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the	No	n/a
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number	No	n/a
in repository (where relevant) <b>OR</b> RRID		
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	No	n/a
number if available, and source (including location		n, a
for collected wild specimens)		
Microbes: provide species and strain, unique	No	n/a
accession number if available, and source		n, a
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	No	n/a
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	No	n/a
obtained from study participants.		
Report on age and sex for all study participants.	No	n/a

## <u>Design</u>

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.	No	n/a
Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Methods/ "Stimulation Protocols"	Page 8/ Line 1-5
Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done, <b>or</b> if they were not carried out.	Methods/"Construction of populations of models of human atrial electrophysiology"	Page 7/Line 11-24
Sample size determination	Methods/"Construction of populations of models of human atrial electrophysiology"	Page 7/Line 16
Randomisation	Methods/"Construction of populations of models of human atrial electrophysiology"	Page 7/Line 15-17
Blinding	No	n/a
Inclusion/exclusion criteria	Methods/"Construction of populations of models of human atrial electrophysiology" Results /" The main hallmarks of the human Pitx2-induced AF electrophysiological phenotype"	Page 7/Line 17-18 and Page 9/Line 9-12
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory	No	n/a
Define whether data describe technical or biological replicates	Methods/" Statistical analysis, software, numerical methods and code availability"	Page 8/Line 20-21
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No	n/a
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	No	n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	No	n/a

## Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is	Methods/"Construction of populations of	Page 7/Line
excluded, and whether the criteria for exclusion were	models of human atrial electrophysiology"	17-18 and
determined and specified in advance.	Results /" The main hallmarks of the human	Page 9/Line
	Pitx2-induced AF electrophysiological	9-12
	phenotype"	
Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of	Methods/" Statistical analysis, software,	Page 8/Line
tests.	numerical methods and code availability"	7-14
Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available,	Methods/" Statistical analysis, software,	Page 8/Line
including protocols for access or restriction on	numerical methods and code availability"	20-22
access.		
If data are publicly available, provide accession	Methods/" Experimental data and	Page 7/Line
number in repository or DOI or URL.	biomarkers"	6-9 and
	Methods/" Statistical analysis, software,	Page 8/Line
	numerical methods and code availability"	20-22
If publicly available data are reused, provide	Methods/" Experimental data and	Page 7/Line
accession number in repository or DOI or URL, where	biomarkers"	6-9
possible.		
Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential	Methods/" Statistical analysis, software,	Page 8/Line
for replicating the main findings of the study:	numerical methods and code availability"	15-22
State whether the code or software is available.	Methods/" Statistical analysis, software,	Page 8/Line
	numerical methods and code availability"	15-22
If code is publicly available, provide accession	Methods/" Statistical analysis, software,	Page 8/Line
number in repository, or DOI or URL.	numerical methods and code availability"	15-22

## **Reporting**

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	Yes	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication	

Article information: http://dx.doi.org/10.21037/atm-20-5660